ClinicalTrials.gg
RecruitingNCT07588230Updated Nov 9, 2026

Serratus Posterior Superior Intercostal Plane Block in Minimally Invasive Cardiac Surgery

An interventional study of Serratus Posterior Superior Intercostal Plane Block With Bupivacaine and Serratus Posterior Superior Intercostal Plane Block With Saline in Heart Valve Disease and Postoperative Pain, sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Heart Valve Diseases with a site in Turkey — 5 open to participants now, 5 under way, none of them phase 3. Heart Valve Diseases · Turkey.

Started
2026
with 4 others
No phase
7 of 16
2 open now
Registered
13th of 16
by date

Among the 16 studies in Heart Valve Diseases with a site in Turkey, this one is one of 5 that started in 2026, is one of 7 with no phase, and was the 13th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

5 of the 16 studies in Heart Valve Diseases with a site in Turkey are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Heart Valve Diseases with a site in Turkey, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled study aims to evaluate the effect of the serratus posterior superior intercostal plane (SPSIP) block on postoperative pain and opioid consumption in patients undergoing minimally invasive cardiac valve surgery via mini-thoracotomy.

Read the detailed description

This study is a prospective, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the analgesic efficacy of the serratus posterior superior intercostal plane (SPSIP) block in patients undergoing minimally invasive cardiac valve surgery via mini-thoracotomy. Postoperative pain following thoracic cardiac surgery may impair respiratory function and delay recovery, making effective analgesia essential.

Participants will be randomly assigned to receive an ultrasound-guided SPSIP block with either bupivacaine or normal saline under identical conditions. All patients will receive standardized general anesthesia and postoperative multimodal analgesia. Blinding will be ensured for patients and outcome assessors.

The study aims to determine whether SPSIP block with local anesthetic reduces postoperative opioid consumption and improves pain control compared to placebo.

03

Conditions studied

  • Heart Valve Disease
  • Postoperative Pain

Keywords

  • Cardiac Surgery
  • Postoperative Pain
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18-75 years
  • I-III
  • Scheduled for elective minimally invasive cardiac valve surgery via mini-thoracotomy
  • Able to understand and use the Numeric Rating Scale (NRS)
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Age >75 years
  • Known allergy or to local anesthetics (e.g., bupivacaine)
  • Coagulopathy or ongoing anticoagulant therapy that cannot be discontinued
  • Infection at the planned block site
  • Chronic opioid use or chronic pain conditions
  • Severe pulmonary disease affecting respiratory assessment
  • Neurological or psychiatric disorders interfering with pain assessment
  • Emergency surgery
  • Pregnancy or breastfeeding
  • Refusal to participate
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Serratus Posterior Superior Intercostal Plane Block with Bupivacaine

    Participants will receive an ultrasound-guided serratus posterior superior intercostal plane (SPSIP) block with bupivacaine prior to surgery, in addition to standard general anesthesia and multimodal analgesia.

    Procedure: Serratus Posterior Superior Intercostal Plane Block With Bupivacaine

  • Placebo comparator
    Serratus Posterior Superior Intercostal Plane Block with Saline

    Participants will receive an ultrasound-guided serratus posterior superior intercostal plane (SPSIP) block with normal saline under identical conditions, in addition to standard general anesthesia and multimodal analgesia.

    Procedure: Serratus Posterior Superior Intercostal Plane Block With Saline

Interventions

  • ProcedureSerratus Posterior Superior Intercostal Plane Block With Bupivacaine

    Participants in this group will receive an ultrasound-guided serratus posterior superior intercostal plane (SPSIP) block prior to surgery using 30 mL of 0.25% bupivacaine, in addition to standard general anesthesia and multimodal analgesia.

    Also known as: SPSIP Block

  • ProcedureSerratus Posterior Superior Intercostal Plane Block With Saline

    Participants in this group will receive an ultrasound-guided placebo block using 30 mL of normal saline under identical conditions, in addition to standard general anesthesia and multimodal analgesia.

06

What researchers measure

Primary outcomes

  1. 24-hour cumulative opioid consumption

    Total opioid consumption within the first 24 hours after surgery, expressed as intravenous morphine milligram equivalents (IV-MME).

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Postoperative pain intensity at rest (NRS)

    Pain intensity at rest measured using the Numeric Rating Scale (0-10).

    Time frame: 4, 6, 12, and 24 hours after surgery

  2. Postoperative pain during movement (NRS)

    Pain intensity during coughing or deep breathing measured using the Numeric Rating Scale (0-10).

    Time frame: 4, 6, 12, and 24 hours after surgery

  3. Time to first rescue analgesia

    Time from the end of surgery to the first administration of rescue analgesia.

    Time frame: Within 24 hours after surgery

  4. Time to extubation

    Time from the end of surgery to extubation.

    Time frame: From the end of surgery until extubation, assessed up to 24 hours

  5. Length of intensive care unit stay

    Duration of stay in the intensive care unit.

    Time frame: Through study completion, an average of 48 hours

  6. Length of hospital stay

    Total duration of hospitalization.

    Time frame: From date of admission until discharge, up to 30 days

  7. Inspiratory Spirometry Test

    Inspiratory spirometry performance will be assessed using an incentive spirometer. Inspiratory capacity will be estimated based on the number of rising balls: 1 ball = 600 mL, 2 balls = 900 mL, and 3 balls = 1200 mL. The score ranges from a minimum of 1 ball to a maximum of 3 balls, with higher scores indicating better inspiratory function.

    Time frame: 4, 6, 12, and 24 hours after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in this article (text, tables, figures, and appendices) will be shared.

Supporting information: Study protocol, Informed consent form

Time frame: Starting 6 months and ending 36 months following article publication.

Access criteria: Data will be available to researchers who provide a methodologically sound proposal. Proposals should be directed to acilfatma@gmail.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 108 non-industry interventional studies with no phase under Heart Valve Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 7 months is below that.

Counting every sponsor, half of 154 studies reached it within 30 months; a quarter within 16 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 14, 2026
StartActual
May 16, 2026
Primary completionEst.
Dec 25, 2026was Oct 2026
CompletionEst.
Dec 26, 2026was Oct 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 25, 2026→Dec 25, 2026
Nov 9, 2026
Study completion
Oct 26, 2026→Dec 26, 2026
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Oct 25, 2026→Dec 25, 2026
    Study completion Oct 26, 2026→Dec 26, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07588230
Lead sponsor
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Responsible party
Fatma Acil,MD (Principal Investigator, Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital) — Principal investigator
First posted
May 14, 2026
Start date
May 16, 2026
Primary completion
Dec 25, 2026 (estimated)
Completion
Dec 26, 2026 (estimated)
Last update
Nov 9, 2026

Study contacts

Fatma Acil, M.D.
Contact
acilfatma@gmail.com
+905337225225
Fatma Acil, M.D.
principal investigator · Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion